Evaluation of delgocitinib for the treatment of moderate to severe chronic hand eczema in adults. (PubMed, Expert Opin Pharmacother) - Jul 11, 2026 - "Alitretinoin, a vitamin A derivate licensed as a systemic treatment option in Europe, has demonstrated efficacy but is accompanied by systemic adverse effects. Delgocitinib is a topical pan-janus kinase (JAK) inhibitor and represents a novel treatment option for CHE with a favorable safety and tolerability profile. Further data on long-term use and real-world effectiveness are still needed."
Journal • Review • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology • Inflammation
|
|
Margitta Worm; Nicole Piaskowski; Philipp Globig
|